Xilio Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Xilio Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2020 to 2023.
  • Xilio Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$14.8M, a 15% increase year-over-year.
  • Xilio Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$65.1M, a 22.7% increase year-over-year.
  • Xilio Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$79.1M, a 11.2% increase from 2022.
  • Xilio Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$89.1M, a 18.8% decline from 2021.
  • Xilio Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$75M, a 37.5% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$79.1M +$10M +11.2% Jan 1, 2023 Dec 31, 2023 10-K 2024-04-01
2022 -$89.1M -$14.1M -18.8% Jan 1, 2022 Dec 31, 2022 10-K 2024-04-01
2021 -$75M -$20.5M -37.5% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-02
2020 -$54.6M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.